In tumors where MYC is not amplified, loss of the tumor suppressor adenomatous polyposis coli and activation of the WNT/β‐catenin pathway lead to transcriptional activation of MYC via TCF transcription factor, a phenomenon occasionally observed in colorectal and prostate cancers (He et al, 1998; Nandana & Chung, 2014). The gene discussed is MYC; the disease is prostate carcinoma.